Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut and focused on targeted protein degradation. Its news flow centers on progress across a pipeline of investigational PROTAC (PROteolysis TArgeting Chimera) protein degraders for oncology and neurodegenerative disorders.
On this ARVN news page, readers can follow company-issued updates on key programs such as vepdegestrant, an investigational PROTAC estrogen receptor degrader for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations; ARV-393, a BCL6 degrader in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma; ARV-806, a KRAS G12D degrader for solid tumors including pancreatic, colorectal and lung cancer; and ARV-102, a LRRK2 degrader being studied in Parkinson’s disease and other neurodegenerative conditions.
Typical ARVN news items include clinical data presentations at major scientific meetings, regulatory milestones such as acceptance of the New Drug Application for vepdegestrant by the U.S. Food and Drug Administration, and preclinical results that characterize the activity of new PROTAC candidates. Arvinas also uses press releases to describe collaboration developments with Pfizer, organizational changes, financial updates and other corporate actions disclosed in its SEC filings.
Investors, clinicians and researchers can use this news feed to track how Arvinas’ PROTAC platform is being applied to targets like estrogen receptor, BCL6, KRAS G12D and LRRK2, and to monitor the timing and content of data readouts, regulatory events and partnership announcements related to ARVN.
Arvinas (NASDAQ: ARVN) presented preclinical data showing enhanced antitumor activity when its PROTAC BCL6 degrader ARV-393 is combined with glofitamab (CD20×CD3) at ASH 2025.
Key findings: concomitant ARV-393 (3 mg/kg) + glofitamab (0.15 mg/kg) produced 81% tumor growth inhibition (TGI) and sequential dosing produced 91% TGI vs 38% and 36% for each agent alone; higher-dose ARV-393 (6 mg/kg) combinations yielded markedly higher tumor regressions (10/10 and 7/8 mice vs 5/11 and 0/11 for single agents). RNA sequencing showed CD20 upregulation and increased interferon/antigen-presentation gene expression. Arvinas plans to initiate a Phase 1 combination cohort in DLBCL in 2026.
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Arvinas (Nasdaq: ARVN) announced multiple abstracts on vepdegestrant (ARV-471) accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025 in San Antonio, TX.
Presentations include subgroup analyses from the phase 3 VERITAC-2 trial versus fulvestrant, ctDNA biomarker analyses from a phase 1/2 study, real-world ESR1 mutation prevalence after 1L therapy, an I-SPY2 endocrine optimization pilot, and a phase 1/2 trial of PF-07248144 combined with vepdegestrant. Pfizer is a development collaborator and Quantum Leap sponsors I-SPY2 EOP. Full abstracts available via the SABCS online program.
Arvinas (NASDAQ: ARVN) reported 3Q2025 results and a corporate update highlighting clinical and preclinical progress, collaboration milestones, and financial positions. Key clinical highlights include ARV-102 showing >90% PBMC LRRK2 reduction and >50% CSF reduction with brain penetration, and ARV-102 effects on distal CSF biomarkers; ARV-806 preclinical potency ~25x–40x versus competitors with >90% degradation for 7 days in models; ARV-027 demonstrated 40–60% muscle polyQ-AR reduction and functional benefit in SBMA mice. Regulatory/commercial: FDA accepted the NDA for vepdegestrant with a PDUFA date of June 5, 2026 and Arvinas/Pfizer will jointly select a commercialization partner. Cash was $787.6M at Sept 30, 2025, funding operations into H2 2028 per management.
Arvinas (NASDAQ: ARVN) will present preclinical data for its PROTAC BCL6 degrader ARV-393 in combination with glofitamab at the 2025 American Society of Hematology (ASH) Annual Meeting.
The poster (Publication No. 1520) is in Session 605: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, on December 6, 2025, 5:30 PM–7:30 PM ET, at OCCC – West Halls B3–B4. The full abstract is available via the ASH online program.
Arvinas (Nasdaq: ARVN) said management will participate in two investor conferences in November 2025: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and the Jefferies London Healthcare Conference on Tuesday, November 18, 2025.
Both presentations will offer a live audio webcast accessible via links and the company’s Events and Presentations web section.
Arvinas (Nasdaq: ARVN) will report third quarter 2025 financial results and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET.
Management will review the company's Q3 2025 financial results and deliver a corporate update. The live webcast is accessible under “Events and Presentations” on Arvinas' investor website and a replay will be available at www.arvinas.com after the event.
Arvinas (Nasdaq: ARVN) announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, presented Oct 24, 2025 at the AACR-NCI-EORTC conference.
Key points: picomolar in vitro KRAS G12D degradation across pancreatic, colorectal and lung lines; >25-fold greater antiproliferative potency versus clinical-stage G12D inhibitors; >40-fold higher KRAS G12D degradation potency versus a clinical-stage G12D degrader; single IV dose produced >90% KRAS G12D degradation for seven days with c-MYC suppression and BIM induction for ≥5 days; ≥30% tumor volume reductions in pancreatic, colorectal CDX and a lung PDX model. ARV-806 is in a Phase 1 trial (NCT07023731).
Arvinas (Nasdaq: ARVN) will present preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The data will be shown as Poster B107 in Poster Session B on October 24, 2025 from 12:30–4:00 PM ET. The full abstract is available in the conference online program.
Arvinas (NASDAQ: ARVN) reported patient-reported outcomes from the Phase 3 VERITAC-2 trial showing vepdegestrant delayed deterioration in overall quality of life, pain, and multiple functioning domains versus fulvestrant in patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.
The trial enrolled 624 patients (270 with ESR1 mutations) across 213 sites in 25 countries; progression-free survival showed a statistically significant improvement and overall survival remains the key secondary endpoint.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
